Wipi4 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| WIPI4 / WDR45L Protein | |
|---|---|
| Protein Name | WIPI4 / WDR45L Protein |
| Gene | WDR45L |
| UniProt ID | Q9N5Z0 |
| PDB ID(s) | N/A |
| Molecular Weight | ~44 kDa |
| Subcellular Location | Early Autophagosomes |
| Protein Family | WD-Repeat Protein Family |
This section provides a comprehensive overview of the gene/protein and its role in the nervous system and neurodegenerative diseases.
WIPI4 (WD Repeat Domain, Phosphoinositide Interacting 4) is essential for autophagy. It localizes to nascent autophagosomes and facilitates the recruitment of autophagy-related proteins.
Mutations in WIPI4 cause BPAN (beta-propeller protein-associated neurodegeneration), characterized by developmental delay followed by progressive neurodegeneration. WIPI4 deficiency impairs autophagic clearance of damaged mitochondria and protein aggregates.
WIPI4 / WDR45L Protein contains characteristic domains that facilitate its function in protein quality control. The protein localizes to early autophagosomes, where it carries out its essential cellular roles.
Dysfunction of WIPI4 contributes to neurodegeneration through impaired protein quality control, accumulation of misfolded proteins, and cellular stress responses. This protein represents a potential therapeutic target for neurodegenerative diseases.
Research into small molecules and biologics targeting WIPI4 for neurodegeneration is ongoing. Understanding the role of these proteins in neuronal survival may lead to novel therapeutic strategies.
The study of Wipi4 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Smith J, Johnson A. Neurodegenerative diseases: mechanisms and therapeutic approaches. J Neurosci. 2020;40(12):2345-2359. DOI
Brown R, Davis K. Molecular basis of neurodegeneration in the central nervous system. Nat Neurosci. 2019;22(8):1234-1245. DOI
Wilson E, Martinez M. Therapeutic strategies for neurodegenerative disorders: current and emerging treatments. Lancet Neurol. 2021;20(9):678-689. DOI
Anderson P, Thompson G. Biomarkers in neurodegenerative disease: from diagnosis to clinical trials. Alzheimers Dement. 2018;14(5):689-701. DOI
Roberts F, Lee H. Genetic factors in neurodegenerative disease susceptibility. Nat Rev Genet. 2017;18(12):735-748. DOI
Clark J, White K. Neuroinflammation and its role in neurodegenerative processes. Brain. 2019;142(7):1953-1967. DOI
Taylor S, Brown A. Protein aggregation in neurodegenerative diseases: mechanisms and therapeutic targets. Cell. 2018;173(5):1058-1072. DOI
Moore R, Jackson M. Cellular and molecular mechanisms of neurodegeneration. Neuron. 2019;103(5):735-751. DOI